Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1996 Nov;61(5):518–520. doi: 10.1136/jnnp.61.5.518

The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease.

T Gasser 1, B Müller-Myhsok 1, A Supala 1, E Zimmer 1, G Wieditz 1, Z K Wszolek 1, P Vieregge 1, V Bonifati 1, W H Oertel 1
PMCID: PMC1074052  PMID: 8937349

Abstract

The frequency of the CYP2D6B allele of the gene for debrisoquine 4-hydroxylase was studied in 115 patients with sporadic idiopathic Parkinson's disease, 55 of their healthy siblings, 63 patients with familial Parkinson's disease, 55 unaffected relatives, and 92 patients with Alzheimer's disease and 73 age matched healthy controls. By contrast with several previous studies, no significant variation of allele frequencies could be found between any of the groups studied. The results argue against a significant role of the CYP2D6 gene in the aetiology of sporadic and familial idiopathic parkinsonism in this patient population.

Full text

PDF
518

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agúndez J. A., Jiménez-Jiménez F. J., Luengo A., Bernal M. L., Molina J. A., Ayuso L., Vázquez A., Parra J., Duarte J., Coria F. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther. 1995 Mar;57(3):291–298. doi: 10.1016/0009-9236(95)90154-X. [DOI] [PubMed] [Google Scholar]
  2. Armstrong M., Daly A. K., Cholerton S., Bateman D. N., Idle J. R. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 1992 Apr 25;339(8800):1017–1018. doi: 10.1016/0140-6736(92)90537-d. [DOI] [PubMed] [Google Scholar]
  3. Gasser T., Wszolek Z. K., Trofatter J., Ozelius L., Uitti R. J., Lee C. S., Gusella J., Pfeiffer R. F., Calne D. B., Breakefield X. O. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol. 1994 Sep;36(3):387–396. doi: 10.1002/ana.410360310. [DOI] [PubMed] [Google Scholar]
  4. Kidd K. K. Associations of disease with genetic markers: déjà vu all over again. Am J Med Genet. 1993 Jul 15;48(2):71–73. doi: 10.1002/ajmg.1320480202. [DOI] [PubMed] [Google Scholar]
  5. Kurth M. C., Kurth J. H. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet. 1993 Oct 15;48(3):166–168. doi: 10.1002/ajmg.1320480311. [DOI] [PubMed] [Google Scholar]
  6. Planté-Bordeneuve V., Bandmann O., Wenning G., Quinn N. P., Daniel S. E., Harding A. E. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy. Mov Disord. 1995 May;10(3):277–278. doi: 10.1002/mds.870100307. [DOI] [PubMed] [Google Scholar]
  7. Planté-Bordeneuve V., Davis M. B., Maraganore D. M., Marsden C. D., Harding A. E. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):911–913. doi: 10.1136/jnnp.57.8.911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Schaid D. J., Sommer S. S. Genotype relative risks: methods for design and analysis of candidate-gene association studies. Am J Hum Genet. 1993 Nov;53(5):1114–1126. [PMC free article] [PubMed] [Google Scholar]
  9. Smith C. A., Gough A. C., Leigh P. N., Summers B. A., Harding A. E., Maraganore D. M., Sturman S. G., Schapira A. H., Williams A. C., Maranganore D. M. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1992 Jun 6;339(8806):1375–1377. doi: 10.1016/0140-6736(92)91196-f. [DOI] [PubMed] [Google Scholar]
  10. Ward C. D., Gibb W. R. Research diagnostic criteria for Parkinson's disease. Adv Neurol. 1990;53:245–249. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES